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ABSTRACT
Aberrant activation of Janus kinase-3 (Jak3) and its key down-stream 
effectors, Signal Transducer and Activator of Transcription-3 (STAT3) and STAT5, 
is a key feature of malignant transformation in cutaneous T-cell lymphoma (CTCL). 
However, it remains only partially understood how Jak3/STAT activation promotes 
lymphomagenesis. Recently, non-coding microRNAs (miRNAs) have been implicated in 
the pathogenesis of this malignancy. Here, we show that (i) malignant T cells display 
a decreased expression of a tumor suppressor miRNA, miR-22, when compared to 
non-malignant T cells, (ii) STAT5 binds the promoter of the miR-22 host gene, and (iii) 
inhibition of Jak3, STAT3, and STAT5 triggers increased expression of pri-miR-22 and 
miR-22. Curcumin, a nutrient with anti-Jak3 activity and histone deacetylase inhibitors 
(HDACi) also trigger increased expression of pri-miR-22 and miR-22. Transfection of 
malignant T cells with recombinant miR-22 inhibits the expression of validated miR-
22 targets including NCoA1, a transcriptional co-activator in others cancers, as well 
as HDAC6, MAX, MYCBP, PTEN, and CDK2, which have all been implicated in CTCL 
SDWKRJHQHVLV,QFRQFOXVLRQZHSURYLGHWKH¿UVWHYLGHQFHWKDWGHUHJXODWHG-DN
STAT3/STAT5 signalling in CTCL cells represses the expression of the gene encoding 
miR-22, a novel tumor suppressor miRNA. 
INTRODUCTION
Cutaneous T-Cell lymphoma (CTCL) is 
characterized by the proliferation of malignant T cells 
LQ D FKURQLF LQÀDPPDWRU\ PLFURHQYLURQPHQW 7KH
etiology of CTCL remains only partially understood 
and, unfortunately, it has not been possible to identify 
RQHXQLI\LQJJHQHWLFHYHQWRU one particular oncogene of 
central importance for the malignant transformation and 
FDQFHU SURJUHVVLRQ ,QVWHDG GHUHJXODWLRQ RI VLJQDOLQJ
SDWKZD\VLQFOXGLQJ6LJQDO7UDQVGXFHUVDQG$FWLYDWRUVRI
7UDQVFULSWLRQ67$7VUFNLQDVHVF0\F&2;1)ț%
GATA3, TOX, and embryonic stem cell regulators appears 
WRSOD\DQLPSRUWDQWUROHLQWKHSDWKRJHQHVLV>@,Q
SDUWLFXODU WKH ,QWHUOHXNLQ UHFHSWRU FRPPRQ JDPPD
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FKDLQ ,/5JF WKH DVVRFLDWHG -DQXV NLQDVH -DN
DQGWKHGRZQVWUHDPHIIHFWRUV67$7DQG67$7KDYH
DWWUDFWHG VXEVWDQWLDO LQWHUHVW LQ WKLV UHJDUG ,QGHHG WKH
,/5JFVLJQDOLQJ F\WRNLQHV ,/ ,/ ,/ ,/
DQG,/DUHLPSOLFDWHGLQHDUO\SDWKRJHQHVLVZKHUHDV
FRQVWLWXWLYH LQWHUOHXNLQLQGHSHQGHQW DFWLYDWLRQ RI WKH
-DN67$7 SDWKZD\ LV EHOLHYHG WR SOD\ D NH\ UROH LQ
SURJUHVVLYHDQGDGYDQFHGGLVHDVH>@7KHDEHUUDQW
DFWLYDWLRQ RI WKH -DN67$7 SDWKZD\ DQG LQWHUOHXNLQ
independent proliferation of malignant T cells appears 
WR EH LQ SDUW D UHVXOW RI GH¿FLHQW H[SUHVVLRQ DQGRU
IXQFWLRQRIQHJDWLYH UHJXODWRUV VXFKDV6XSSUHVVRUV2I




of angiogenetic factors, and (iii) confers resistance to 
WUHDWPHQWZLWK+'$&LQKLELWRUVLQPDOLJQDQW7FHOOV>
@<HWUHODWLYHO\OLWWOHLVNQRZQDERXW67$7
target genes in CTCL and how STAT3, STAT5, and their 
FRDFWLYDWRUVDQGRUFRUHSUHVVRUVUHJXODWHRIH[SUHVVLRQ
RIGLVHDVHDVVRFLDWHGJHQHV
5HFHQWO\ D QHZ FODVV RI SRVWWUDQVFULSWLRQDO
UHJXODWRUV QRQFRGLQJ PLFUR51$V PL51$V KDV
UHFHLYHGFRQVLGHUDEOHDWWHQWLRQLQUHODWLRQWR&7&/6NLQ
OHVLRQVIURP&7&/SDWLHQWVGLVSOD\HGDGLVWLQFWPL51$
H[SUHVVLRQ VLJQDWXUH )XUWKHUPRUH D PLQLPDO PL51$
FODVVL¿HU FRQVLVWLQJ RI RQO\ WKUHH PL51$V PL5
PL5DQGPL5ZDVDEOHWRGLVWLQJXLVKEHWZHHQ






SURPRWHV PDOLJQDQW SUROLIHUDWLRQ > @ &RQYHUVHO\
WKHH[SUHVVLRQRIRWKHUPL51$V LVRIWHQ ORVW LQ&7&/
skin lesions when compared to benign dermatoses and 
QRUPDOVNLQ>@6RPHRIWKHVHPL51$VDUHQRZ
recognized to act as tumor suppressors as documented by 
WKHLUDELOLW\WRLQKLELWWXPRUJURZWKDQGRUPHWDVWDVLV>
@PLUH[SUHVVLRQLVGRZQUHJXODWHGLQDQXPEHURI
cancers and has been assigned a role of tumor suppressor 
PL51$LQFRORQDQGEUHDVWFDQFHUV>@,QDUHFHQW
















Loss of miR-22 expression in malignant T cells






UHDFWLYH7FHOO OLQHVREWDLQHG IURP&7&/VNLQ OHVLRQV
0\/D DQG 0\6L DQG SVRULDWLF VNLQ 3625
Figure 1: Expression of mature and primary miR-22 in CTCL as determined by qPCR. a.PL5H[SUHVVLRQ LQQRQ
PDOLJQDQW0\/D0\6LDQGPDOLJQDQW0\/D0\/D6H$[3%%&7&/7FHOOOLQHVDVZHOODVRQH7FHOOOLQHGHULYHG
IURPSVRULDVLVYXOJDULVSDWLHQW3625UHIHUHQFH8n b.SULPDU\PL5SULPL5H[SUHVVLRQLQQRQPDOLJQDQW0\/DDQG





WR QRQPDOLJQDQW7 FHOO OLQH )LJXUH % 6LPLODUO\ LQ
6p]DU\V\QGURPHSHULSKHUDOPRQRQXFOHDUFHOOVPL5
H[SUHVVLRQ ZDV GHFUHDVHG ZKHQ FRPSDUHG WR WKH FHOOV
IURPKHDOWK\YROXQWHHUV)LJXUH&
Jak3/STAT signaling represses miR-22 expression
,O5JVLJQDOLQJF\WRNLQHV UHJXODWH H[SUHVVLRQRI
PXOWLSOH PL51$V WKURXJK WKH -DN67$7 SDWKZD\ $V
VKRZQ LQ)LJXUH ,/ LQGXFHGDVLJQL¿FDQWGHFUHDVH
LQ PL5 H[SUHVVLRQ LQ QRQPDOLJQDQW 7 FHOO OLQHV
0\/D )LJXUH  OHIW SDQHO DQG 0\6L )LJXUH 
ULJKWSDQHO&RQYHUVHO\LQKLELWLRQRI,/5VLJQDOLQJE\
Figure 2: Effect of the T cell growth factor, IL-2, on miR-22 expression. ([SUHVVLRQRIPL5LQ,/VHQVLWLYHQRQPDOLJQDQW
&7&/7FHOOV0\/DDQG0\6L&HOOVZHUHGHSOHWHGRI,/IRUKRXUV±,/RUGHSOHWHGRI,/IRUKRXUVIROORZHGE\
KRXUVRI,/VXSSOHPHQWDWLRQ,/PL5H[SUHVVLRQZDVGHWHUPLQHGE\T3&5XVLQJ8DVDUHIHUHQFHn 








GLVSOD\ D FRQVWLWXWLYH DEHUUDQW -DN DFWLYDWLRQ >@
FXUFXPLQSURGXFHGDQXSUHJXODWLRQRIPL5)LJXUH
$ULJKW1RWDEO\FXUFXPLQDOVRHQKDQFHGSULPL5
H[SUHVVLRQ LQ PDOLJQDQW 0\/D DQG 6H$[ 7 FHOOV
)LJXUH%ULJKWDQGFHQWUDOSDQHOVDQGLQ,/WUHDWHG
QRQPDOLJQDQW 7 FHOOV )LJXUH % OHIW SDQHO 6LQFH






2YHUDOO WKHVH¿QGLQJV LQGLFDWH WKDW -DNDFWLYDWLRQ
UHSUHVV PL5 H[SUHVVLRQ LQ PDOLJQDQW 7 FHOOV 6LQFH




VKRZV H[SUHVVLRQ FKDQJHV LQ PL5 )LJXUH $ DQG






STAT binding to the miR-22 host gene promoter
,QDGGLWLRQWRWKHLUUROHDVWUDQVFULSWLRQDODFWLYDWRUV
67$7FDQDOVRIXQFWLRQDVUHSUHVVRUVRI WUDQVFULSWLRQ
Thus, in some cancer models STAT3 represses the 
H[SUHVVLRQ RI PXOWLSOH JHQHV LQFOXGLQJ NH\ UHJXODWRUV
of stress responses and neoplastic transformation such 
DV S >@ ,QWHUHVWLQJO\ 67$7 KDV EHHQ LPSOLFDWHG
LQ ERWK WUDQVFULSWLRQDO DFWLYDWLRQ DQG UHSUHVVLRQ RI WKH
RQFRPL5>@ZKLFKSUREDEO\UHÀHFWVDFHOO
FRQWH[WGHSHQGHQW UHFUXLWPHQWRI FRDFWLYDWRUV DQGFR
UHSUHVVRUVVXFKDV%/,03>@/LNHZLVH67$7FDQ
IXQFWLRQDVDWUDQVFULSWLRQDODFWLYDWRURUDWUDQVFULSWLRQDO
UHSUHVVRU >@ $FFRUGLQJO\ ZH H[DPLQHG ZKHWKHU
VL51$ PHGLDWHG GHSOHWLRQ RI 67$7 DQG 67$7
LQÀXHQFHG WKH H[SUHVVLRQ RI WKH SULPDU\ WUDQVFULSW RI
WKH PL5 JHQH PL5+*&2UI SULPL5
$V VKRZQ LQ )LJXUH $ VL51$PHGLDWHG LQKLELWLRQ
RI 67$7 67$7$ DQG 67$7% WULJJHUHG LQFUHDVHG
H[SUHVVLRQRISULPL5VXJJHVWLQJWKDWWKH\GLUHFWO\RU
LQGLUHFWO\UHSUHVVWUDQVFULSWLRQRIPL5+*
To elucidate whether STAT3 and STAT5 directly 
ELQGWRWKHPL5+*ZHSHUIRUPHGROLJRQXFOHRWLGH
based binding assay using a synthetic oligonucleotide 
FRUUHVSRQGLQJWRD67$7ELQGLQJVHTXHQFHLQWKHPL5
+*$VVKRZQLQ)LJXUH&S<67$7DQGWRDOHVVHU
H[WHQG S<67$7 FRSUHFLSLWDWHG ZLWK WKH PL5+*
ROLJRQXFOHRWLGH1RWDEO\WKHSKRVSKRU\ODWLRQRI67$7
and STAT5 was almost completely blocked by pre-









To address further whether STAT proteins 
GLUHFWO\ ELQG WKH PL5+* SURPRWHU LQ PDOLJQDQW 7
FHOOV ZH SHUIRUPHG &KURPDWLQ ,PPXQH3UHFLSLWDWLRQ
IROORZHG E\ '1$ VHTXHQFLQJ &K,3VHT WR LGHQWLI\
WUDQVFULSWLRQDOWDUJHWVRI67$7DQGRWKHUSXWDWLYHUHOHYDQW
WUDQVFULSWLRQ IDFWRUV LQ D PRUH SK\VLRORJLFDO VHWWLQJ
&K,3VHTDQDO\VLVRI67$7SUHFLSLWDWHGFKURPDWLQIURP
PDOLJQDQW 0\/D FHOOV \LHOGHG DQ HQULFKPHQW RI
UHDGV FRPSULVLQJ D SURPRWRU UHJLRQ RI WKH PL5+*
&2UI)LJXUH',QFRQWUDVWRQO\IHZUHDGVIRU
WKH PL5+* SURPRWHU ZHUH GHWHFWHG LQ FKURPDWLQ
SUHFLSLWDWHG ZLWK 67$7 DQWLERG\ )LJXUH ' 6LQFH












UDEELW ,J*&RQVLVWHQWZLWKRXU HDUOLHU H[SHULHPHQWDO
¿QGLQJV&K,3VHT3&5DPSOL¿FDWLRQ)LJXUH(VKRZHG
D PDUNHG HQULFKPHQW RI WKH VHTXHQFH UHSUHVHQWLQJ WKH
PL5+*SURPRWHULQVDPSOHVSUHFLSLWDWHGZLWK67$7
antibody, whereas STAT3-precipitated samples produced 
D OHVV SURQRXQFHG EDQG ,Q D SDUDOOHO H[SHULPHQW ZH
REVHUYHG HQULFKPHQW RI WKH VHTXHQFH UHSUHVHQWLQJ WKH
67$7 ELQGLQJ VLWH LQ WKH %,& SURPRWHU LQ VDPSOHV
precipitated with STAT5 antibody whereas STAT3-
SUHFLSLWDWHG VDPSOHV ZHUH QHJDWLYH )LJXUH ( ORZHU
SDQHO VKRZLQJ WKH VSHFL¿FLW\ RI WKH &K,3 DVVD\ DQG
FRQ¿UPLQJSUHYLRXVGDWDRQDVHOHFWLYH67$7ELQGLQJWR
WKH%,&SURPRWHU>@7DNHQWRJHWKHUWKHVHGDWDLQGLFDWH
that STAT5, and seemingly to a lesser degree, STAT3 bind 
WRWKHPL5+*SURPRWHU
HDAC inhibitors induce expression of miR-22 in 
malignant T cells
,Q DGGLWLRQ WR D GLUHFW WUDQVFULSWLRQDO UHSUHVVLRQ
of target genes, STAT3 and STAT5 may also repress 
transcription through the recruitment of transcriptional co-
UHSUHVVRUVVXFKDV(=+DQG+'$&V>@+HQFHZH






the treatment of CTCL, triggered a profound, time- and 




Figure 5: Transient knockdown of STAT3 and STAT5 genes increases expression of mature miR-22 in malignant CTCL 




Figure 6: Binding of STAT transcription factors to the the miR-22HG C17orf91 and upstream promoter regions. a. 












Elucidating miR-22 targets in malignant T cells
PL5 KDV EHHQ DVVLJQHG D UROH RI D WXPRU
VXSSUHVVRU LQ YDULRXV VROLG WXPRUV UHYLHZHG LQ >@
as well as some hematological malignancies (acute 
lymphoblastic leukemia, multiple myeloma and anaplastic 




FRDFWLYDWRUVUHJXODWRUV RI F0\F >@ FRXOG
EHLQYROYHGLQWKHSDWKRJHQHVLVRI&7&/7RGHWHUPLQH
whether these proteins were susceptible to inhibition by 
PL5LQPDOLJQDQW7FHOOVZHXVHGHOHFWURSRUDWLRQWR





FRQWURO )LJXUH $$FFRUGLQJO\ D PDUNHG LQKLELWLRQ
E\RI0$;0<&%31&R$DQG37(1ZDV





7KH SURIRXQG LQKLELWLRQ RI 1&R$ E\ PL5
is of particular interest as NCoA1 is a transcriptional 
FRDFWLYDWRU UHJXODWLQJ PXOWLSOH RQFRJHQLF SDWKZD\V
associated with disease progression and metastasis 
IRUPDWLRQ LQ EUHDVW DQG SURVWDWH FDQFHU >@ :KHQ
FRUUHODWLQJPL5DQG1&R$H[SUHVVLRQLQPDOLJQDQW
DQG QRQPDOLJQDQW 7 FHOOV E\ 57T3&5 )LJXUH %
D UHODWLYHO\ KLJK PL5 H[SUHVVLRQ ZDV DVVRFLDWHG
ZLWKDORZ1&R$H[SUHVVLRQLQQRQPDOLJQDQW7FHOOV








'PL5 WULJJHUHGD VLJQL¿FDQWGHFUHDVH LQ1&R$




PL5 KDV UHFHQWO\ EHHQ DVVLJQHG WKH UROH RI D
WXPRUVXSSUHVVRUPL51$DQGORZH[SUHVVLRQKDVEHHQ
UHSRUWHG LQ DGYDQFHG GLVHDVH DQG PHWDVWDVLV LQ VHYHUDO
VROLGFDQFHUVUHYLHZHGLQ>@,QWKLVZRUNZHSURYLGH
PHFKDQLVWLFHYLGHQFHRIGH¿FLHQWH[SUHVVLRQDQGSXWDWLYH




2XU H[SHULPHQWDO PROHFXODU VWXGLHV LQGLFDWH WKDW
WKH REVHUYHG ORZ H[SUHVVLRQ RI PL5 LQ &7&/ ZDV
GXH WR FRQVWLWXWLYH UHSUHVVLRQ RI PL5 WUDQVFULSWLRQ
E\ DEHUUDQW -DN67$7 VLJQDOLQJ LQ PDOLJQDQW 7 FHOOV









LQKLELWRUV SOD\ DQ LPSRUWDQW UROH LQ UHJXODWLQJ PL5
H[SUHVVLRQ 0RVW LPSRUWDQWO\ RXU UHVXOWV GHPRQVWUDWH
WKDWIRUFHGH[SUHVVLRQRIPL5LQPDOLJQDQWFHOOOLQHV
LQKLELWV H[SUHVVLRQ RI D QXPEHU RI FULWLFDO RQFRJHQHV
LQFOXGLQJ0$;0<&%31&R$DQG&'.
,WLVQRZZHOOHVWDEOLVKHGWKDWLQDGGLWLRQWRWKHLU














DERXW WKHPHFKDQLVPV LQYROYHG LQ67$7DQG67$7
PHGLDWHGUHSUHVVLRQRIJHQHWUDQVFULSWLRQ6WHULFKLQGUDQFH
by STAT proteins and recruitment of other co-repressors 
might account for their function as transcriptional 





GHSHQGLQJ RQ WKH FHOOXODU FRQWH[W UHSUHVV RU DFWLYDWH
transcription through de-acetylation of STAT proteins 
DQG RWKHU PROHFXOHV LQ WKH WUDQVFULSWLRQDO FRPSOH[HV
$Q LQKLELWRU RI (=+V KDG QR HIIHFW RQ WKH H[SUHVVLRQ
RISULPL5ZKHUHDVLQKLELWRUVRI+'$&VLQGXFHGD
SURIRXQGXSUHJXODWLRQLQPL5H[SUHVVLRQVXJJHVWLQJ




YDOLGDWHG PL5 WDUJHWV 6SHFL¿FDOO\ ZH LQYHVWLJDWHG
WKHHIIHFWRIPL5RQWKHH[SUHVVLRQRI1&R$0$;
0<&%3 +'$& +'$& &'. DQG 37(1 DOO RI
ZKLFK KDYH LQGHSHQGHQWO\ EHHQ YDOLGDWHG DV PL5
WDUJHWV >@&RQVWLWXWLYHH[SUHVVLRQ






play a pathogenic role in CTCL due to their effect on the 
&0\FRQFRJHQH>@
:H WKHUHIRUH SURSRVH D PRGHO ZKHUH PL5
H[SUHVVLRQ LV ORZ LQ PDOLJQDQW 7 FHOOV DQG LV GRZQ
UHJXODWHG E\ ,/ LQ QRUPDO 7 FHOOV ZKLOH 0$; DQG






NCoA1, also known as the steroid receptor co-
DFWLYDWRU 65& LV D WUDQVFULSWLRQDO FRDFWLYDWRU DQG
UHSUHVVRU QRW SUHYLRXVO\ GHVFULEHG LQ O\PSKRPD EXW
linked to oncogenesis in malignancies such as carcinoma 
RIEUHDVWRYDULDQDQGSURVWDWHUHYLHZHGE\:DOVK>@
,QGHHG JOREDO JHQH UHSUHVVLRQ E\ 1&R$ SURPRWHV
RQFRJHQHVLVDQGPHWDVWDWLFVSUHDGLQEUHDVWFDQFHU>
@ ,QWHUHVWLQJO\ WKH PDMRU FOLQLFDO LPSRUWDQFH RI DQ
LQFUHDVHGH[SUHVVLRQRI1&R$LQSDWLHQWVZLWKDGYDQFHG
FDQFHUUHODWHVWRWKHGHYHORSPHQWRIGUXJUHVLVWDQFH>
@ )RU LQVWDQFH 1&R$ SURWHFWV FDQFHU FHOOV IURP




H[SUHVVLRQ DQG IXQFWLRQ >@ $V 1&R$ UHJXODWHV
UHWLQRLGVLJQDOLQJDQGVHYHUDORWKHUQXFOHDUUHFHSWRUVLQ
addition to the steroid receptor, studies are in progress to 
address whether NCoA1 plays a role in drug resistance in 
&7&/DQGZKHWKHUFRWUDQVIHFWLRQRIPL5SRWHQWLDWHV
WKH HI¿FDF\RI DQWLFDQFHU WKHUDSLHV DQGGUXJV VXFK DV
EH[DURWHQHDQGWD]DURWHQHDQGRWKHUWUHDWPHQWPRGDOLWLHV
,QGHHG LQ D VWXG\ RQ WKH HI¿FDF\ RI H[WUDFRUSRUHDO
SKRWRFKHPRWKHUDS\ (&3 LQ &7&/ %HUJHU HW DO
>@ UHSRUWHG RQ D GUDPDWLF HIIHFW RQ OHXNRF\WH JHQH
H[SUHVVLRQ7KHVWXG\GLGQRWLQFOXGHLQIRUPDWLRQRIPL5
H[SUHVVLRQEXWDQDO\VLVRI WKH UDZPLFURDUUD\GDWD
VHW REWDLQHG IURP 1&%, *6( 6XSSOHPHQWDU\
)LJXUH6$&LQGLFDWHVWKDWDVXEVHWRIPL5WDUJHW
JHQHV  JHQHV ZHUH VLJQL¿FDQWO\ DOWHUHG IROORZLQJ
(&3!IROGFKDQJHp6XSSO)LJXUH6'
7KHVH LQFOXGHG YDOLGDWHG PL5 WDUJHWV 1&R$ DQG
37(1H[DPLQHGLQWKHFXUUHQWVWXG\ZKLFKZHUHERWK





5HFHQW GDWD LQ PLFH GHPRQVWUDWHG WKDW ORFNHG
QXFOHRWLGH DFLG /1$PRGL¿HG ROLJRQXFOHRWLGHV KDYH
promising therapeutic potentials and are now tested 
LQ D SKDVH RQH FOLQLFDO WULDO >@ 6LQFH /1$PRGL¿HG
ROLJRQXFOHRWLGHV FDQ EH GHVLJQHG WR PLPLF ERWK PL5
agonists and antagonists, it may be speculated that LNA-
EDVHG PL5 PLPLFV PLJKW DOVR KDYH D WKHUDSHXWLF
SRWHQWLDOLQFDQFHUWUHDWPHQW
,Q FRQFOXVLRQ ZH GHPRQVWUDWH IRU WKH ¿UVW WLPH
WKDW PL5 H[SUHVVLRQ LV GRZQUHJXODWHG LQ &7&/
malignant T cells and propose a molecular mechanism, 
ZKHUH DEHUUDQW -DN67$7 VLJQDOLQJ OHDGV WR 67$7
67$7 DFWLYDWLRQ DQG ELQGLQJ WR LWV FRJQDWH VHTXHQFH
RQ WKH PL5+* SURPRWHU 7KLV ELQGLQJ OHDGV WR D
GLUHFWWUDQVFULSWLRQDOUHSUHVVLRQRIWKHJHQH:HIXUWKHU
demonstrate that normal function of this tumor suppressor 
PLFUR51$ LV WR GRZQUHJXODWH D QXPEHU RI SXWDWLYH









Cell lines and culture
0DOLJQDQW 7 FHOO OLQHV 0\/D 0\/D
3%%DQG6H$[ZHUHHVWDEOLVKHGIURPSDWLHQWVGLDJQRVHG
ZLWK &7&/ > @ 0\/D DQG 0\6L DUH QRQ















FHOOV 3%0&V ZHUH LVRODWHG IURP D SDWLHQW GLDJQRVHG




-$. LQKLELWRU ,, &DOELRFKHP 6DQ 'LHJR &$




%XW\UDWH (Q]R /LIH 6FLHQFHV 3O\PRXWK 0HHWLQJ 3$
86$']1HSK\GURFKORULGH6LJPD$OGULFK
Antibodies
Antibodies used in this work are commercially 
DYDLODEOHDQGZHUHREWDLQHGDVIROORZV1&2$DQWLERG\
IURP /LIH6SDQ %LRVFLHQFH 6HDWWOH :$ 86$ /6
%S\67$7DQWLERG\IURP1DQRWRROV'HQ]OLQJHQ
*HUPDQ\ 67$7( 67$7D DQG
67$7EDQWLERGLHVIURP6DQWD&UX]%LRWHFKQRORJ\6DQWD
&UX]&$86$/6&&VF*S\
67$7 67$7 67$7 5HO$ 5HO% +LVWRQH + DQG
UDEELW,J*DQWLERGLHVIURP&HOO6LJQDOLQJ7HFKQRORJLHV
%HYHUO\ 0$ 86$    




%LRWLQ\ODWHG ROLJRQXFOHRWLGHV ZHUH GHVLJQHG
complementary to the predicted STAT binding 
site (according to the transcription factor search 
GDWDEDVH 7)6($5&+ YHUVLRQ  KWWSZZZ
FEUFMSSDSLDKRZWRXVHKRZWRXVHBWIVHDUFKKWPO 













WKH VDPSOHV ZHUH GHQDWXUHG DW & IRU  PLQ DQG
VXEVHTXHQWO\VXEMHFWHGWR6'63$*(DQGEORWWHGIRUS<
67$7DQGS<67$7
&KURPDWLQ ,PPXQRSUHFLSLWDWLRQ &K,3 ZDV
SHUIRUPHGXVLQJ6LPSOH&K,3®(Q]\PDWLF&KURPDWLQ,3
NLW $JDURVH %HDGV IURP &HOO 6LJQDOLQJ7HFKQRORJLHV
%HYHUO\ 0$ 86$ DV SUHYLRXVO\ GHVFULEHG >@
Cross-linked chromatin fragments were captured with 
DQWLERGLHVDJDLQVW67$767$75(/$5(/%+LVWRQH
+ SRVLWLYH FRQWURO RU UDEELW ,J* QHJDWLYH FRQWURO
3&5ZDVSHUIRUPHGRQLPPXQRSUHFLSLWDWHGDQGFRQWURO
'1$VDPSOHVXVLQJSULPHUVIRUUHJLRQVXSVWUHDPRIWKH
SURPRWHUV &RUI PL5+* IRUZDUG VHTXHQFH


















&HOO SHOOHWV ZHUH UHVXVSHQGHG LQ X/ WUDQVIHFWLRQ
VROXWLRQ ,QJHQLR (OHFWURSRUDWLRQ VROXWLRQ 0LUXV %LR
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0DGLVRQ :, 86$ ZLWK  QPRO RI WKH UHVSHFWLYH
VL51$V DQG WUDQVIHFWHG ZLWK DQ $PD[D 1XFOHRIHFWRU
$PD[D*PE+&RORJQH*HUPDQ\







Protein extraction and western blotting
3URWHLQZDVH[WUDFWHGIURP cells persample 
DQG VXEMHFWHG WR 6'63$*( DQG :HVWHUQ EORWWLQJ DV
GHVFULEHGSUHYLRXVO\>@>@








([SUHVVLRQ RI 8  ZDV XVHG DV D UHIHUHQFH
)RUTXDQWL¿FDWLRQRIH[SUHVVLRQRISULPL5RUYDULRXV
P51$V51$H[WUDFWLRQZDVSHUIRUPHGZLWKWKH51HDV\
0LQL .LW 4LDJHQ 9DOHQFLD &$ 86$ F'1$ ZDV
VXEVHTXHQWO\WUDQVFULEHGXVLQJWKH+LJK&DSDFLW\F'1$
5HYHUVH 7UDQVFULSWLRQ .LW IROORZHG E\ 3&5 DQDO\VLV
XVLQJ 7DT0DQ® *HQH ([SUHVVLRQ $VVD\V SULPL5
+VBSUL1&2$+V&'.+V


















































RI (DUO\6WDJH 0\FRVLV )XQJRLGHV - ,QYHVW 'HUPDWRO





(ULNVHQ .: 0DWKLHVHQ $0 %RYLQ /) *QLDGHFNL 5
*HLVOHU&5\GHU/3=KDQJ4:DVLN0$2GXP1HW
DO 0DOLJQDQW 7UHJV H[SUHVV ORZ PROHFXODU VSOLFH IRUPV
RI)2;3LQ6p]DU\V\QGURPH/HXNHPLD

 &KDQJ739DQFXURYD ,1)ț%IXQFWLRQDQG UHJXODWLRQ
LQFXWDQHRXV7FHOOO\PSKRPD$P-&DQFHU5HV

 *HVNLQ /- 9LUDJRYD 6 6WRO] '% )XVFKLRWWL 3
,QWHUOHXNLQ LV RYHUH[SUHVVHG LQ FXWDQHRXV 7FHOO
Oncotarget20566www.impactjournals.com/oncotarget
O\PSKRPD FHOOV DQG UHJXODWHV WKHLU SUROLIHUDWLRQ %ORRG
GRLKWWSG[GRLRUJEORRG






VWHP FHOO DQG RWKHU GHYHORSPHQWDO JHQHV LQ &XWDQHRXV















,+ /LWPDQ 7 -¡QVRQ / +DJHGRUQ 3+ .UHMVJDDUG 7
*QLDGHFNL 5 %RQHIHOG &0 6NRY / *HLVOHU & HW DO
67$7PHGLDWHG H[SUHVVLRQ RI RQFRJHQLF PL5 LQ
FXWDQHRXV7FHOOO\PSKRPD&HOO&\FOH
 $EUDKDP50=KDQJ42GXP1:DVLN0$7KHUROHRI




 H[SUHVVLRQ SURWHFWV 7FHOO O\PSKRPD DJDLQVW JURZWK
LQKLELWLRQE\,)1DOSKD/HXNHPLD
 %UHQGHU & 1LHOVHQ 0 .DOWRIW . 0LNNHOVHQ * =KDQJ
4 :DVLN 0 %LOOHVWUXS 1 2GXP 1 67$7PHGLDWHG
FRQVWLWXWLYH H[SUHVVLRQ RI 62&6 LQ FXWDQHRXV 7FHOO
O\PSKRPD%ORRG











Spontaneous interleukin-5 production in cutaneous T-cell 
O\PSKRPD OLQHV LV PHGLDWHG E\ FRQVWLWXWLYHO\ DFWLYDWHG
6WDW%ORRG
 0DU]HF 0 +DODVD . .DVSU]\FND 0 :\VRFND 0 /LX






0$ 5DOINLDHU ( :RHWPDQQ $ 2GXP 1 0DOLJQDQW
&XWDQHRXV7&HOO/\PSKRPD&HOOV([SUHVV,/8WLOL]LQJ
WKH -DN 6WDW6LJQDOLQJ3DWKZD\ - ,QYHVW'HUPDWRO

 .UHMVJDDUG7/LWYLQRY,9:DQJ<;LD/:LOOHUVOHY




 )DQWLQ 95 /RERGD $ 3DZHOHW] &3 +HQGULFNVRQ 5&
3LHUFH -: 5RWK - D /L / *RRGHQ ) .RUHQFKXN 6




 5DOINLDHU 8 +DJHGRUQ 3+ %DQJVJDDUG 1 /¡YHQGRUI
0% $KOHU &% 6YHQVVRQ / .RSS ./ 9HQQHJDDUG
07 /DXHQERUJ % =LEHUW -5 .UHMVJDDUG 7 %RQHIHOG
&0 6¡NLOGH 5 HW DO 'LDJQRVWLF PLFUR51$ SUR¿OLQJ





HW DO 9DOLGDWLRQ RI D GLDJQRVWLF PLFUR51$ FODVVL¿HU LQ










/ :DVLN 0 %RQHIHOG &0 *HLVOHU & .UHMVJDDUG 7 HW
DO0LFUR51$([SUHVVLRQLQ(DUO\0\FRVLV)XQJRLGHV,V
'LVWLQFWO\'LIIHUHQWIURP$WRSLF'HUPDWLWLVDQG$GYDQFHG



















 %DUDQZDO 6 $ODKDUL 6. PL51$ FRQWURO RI WXPRU FHOO
LQYDVLRQ DQG PHWDVWDVLV ,QW - &DQFHU  























carcinoma and correlated with prognosis , suppresses cell 







 1LX * :ULJKW ./ 0D < *DEULHOD 0 +XDQJ 0 ,UE\





















6WDWGHSHQGHQW JHQH H[SUHVVLRQ LQ 6H]DU\ 6\QGURPH
&DQFHU5HV





H[SUHVVLRQ E\ ELQGLQJ WR D UHJXODWRU\ UHJLRQ IUHTXHQWO\
PXWDWHGLQO\PSKRPDV2QFRJHQH
 0LNORVV\*+LOODUG767XUNVRQ-7KHUDSHXWLFPRGXODWRUV
RI 67$7 VLJQDOOLQJ IRU KXPDQ GLVHDVH 1DW 5HY 'UXJ
'LVFRY
 +RXU 7& &KHQ - +XDQJ &< *XDQ -< /X 6+ 3X
<6&XUFXPLQHQKDQFHVF\WRWR[LFLW\RIFKHPRWKHUDSHXWLF
DJHQWV LQ SURVWDWH FDQFHU FHOOV E\ LQGXFLQJ S:$)








UHOHYDQFH RI PL51$ H[SUHVVLRQ VLJQDWXUHV LQ SULPDU\
SODVPDFHOOOHXNHPLD&OLQFDQFHU5HV
 /LRQHWWL 0 $JQHOOL / 0RVFD / )DEULV 6 $QGURQDFKH
$ 7RGRHUWL . 5RQFKHWWL ' /DPEHUWHQJKL ' * 1HUL





 /LX & ,TEDO - 7HUX\D)HOGVWHLQ - 6KHQ < 'DEURZVND
0-'\ENDHU./LP063LYD5%DUUHFD$3HOOHJULQR
(6SDFFDURWHOOD(/DFKHO&0.XFXN&HWDO0LFUR51$
H[SUHVVLRQ SUR¿OLQJ LGHQWL¿HV PROHFXODU VLJQDWXUHV



















2VWHRJHQLF 'LIIHUHQWLDWLRQ DQG ,QKLELWV $GLSRJHQLF
'LIIHUHQWLDWLRQ RI +XPDQ $GLSRVH 7LVVXH'HULYHG








 'H 0DWWRV 6) (VVD¿ $ 6RHLUR , 3LHWHUVHQ $0













7 :DVLN 0$ 67$7DQG '1$ PHWK\OWUDQVIHUDVH
PHGLDWHG HSLJHQHWLF VLOHQFLQJ RI 6+3 W\URVLQH
phosphatase tumor suppressor gene in malignant T 
O\PSKRF\WHV31$6
 7DQ * 6KL < :X =+ 0LFUR51$ SURPRWHV FHOO
VXUYLYDOXSRQ89UDGLDWLRQE\UHSUHVVLQJ37(1%LRFKHP
%LRSK\V5HV&RPPXQ











































 <X + :X 0 =KDR 3 +XDQJ < :DQJ : <LQ :
1HXURSURWHFWLYH HIIHFWV RI YLUDO RYHUH[SUHVVLRQ RI
PLFUR51$LQUDWDQGFHOOPRGHOVRIFHUHEUDOLVFKHPLD
UHSHUIXVLRQLQMXU\-&HOO%LRFKHP
 %HUJHU & +RIIPDQQ . 9DVTXH] -* 0DQH 6 /HZLV -
)LOOHU 5 =KDR + 'XUD]]R 7 %DLUG $ /LQ : )RVV )
&KULVWHQVHQ,*LUDUGL0HWDOFRQWULEXWLRQWRWKHFOLQLFDO
HI¿FDF\ RI H[WUDFRUSRUHDO SKRWRFKHPRWKHUDS\ 5DSLG









cytokine-dependent continuous human T-lymphocyte cell 
OLQHV&DQFHU*HQHW&\WRJHQHW
 :RHWPDQQ $ /RYDWR 3 (ULNVHQ .: .UHMVJDDUG 7
/DEXGD7=KDQJ40DWKLHVHQ$0*HLVOHU&6YHMJDDUG
$:DVLN0$2GXP11RQPDOLJQDQW7FHOOVVWLPXODWH








 .UHMVJDDUG 7 :LOOHUVOHY2OVHQ $ /LQGDKO /0
%RQHIHOG &0 .RUDORY 6% *HLVOHU & :DVLN 0$
*QLDGHFNL5.LOLDQ0 ,YHUVHQ/:RHWPDQQ$2GXP







 +RIPDQQ % 2GXP 1 3ODW] 3 5\GHU /3 6YHMJDDUG
$ 1HLOVHQ -2 ,PPXQRORJLFDO VWXGLHV LQ DFTXLUHG
LPPXQRGH¿FLHQF\ V\QGURPH )XQFWLRQDO VWXGLHV RI
O\PSKRF\WH VXESRSXODWLRQV 6FDQG - ,PPXQRO 

